Practical experiences of adopting assurance as a quantitative framework to support decision making in drug development. (10th April 2018)

• Record Type: Journal Article
• Authors: Crisp, Adam; Miller, Sam; Thompson, Douglas; Best, Nicky
• Other Names: Morgan David guestEditor.
• Is Part Of: Pharmaceutical statistics. Volume 17:Number 4(2018)
• Page Start: 317
• Page End: 328
• Publication Date: 2018-04-10
• Subjects: Bayesian clinical trial design -- informative priors -- probability of success -- prior elicitation; Pharmacy -- Statistical methods -- Periodicals; Pharmacy -- Statistics -- Periodicals; 615.10727
• DOI: 10.1002/pst.1856
• Languages: English
• ISSNs: 1539-1604

Abstract

Abstract : All clinical trials are designed for success of their primary objectives. Hence, evaluating the probability of success (PoS) should be a key focus at the design stage both to support funding approval from sponsor governance boards and to inform trial design itself. Use of assurance —that is, expected success probability averaged over a prior probability distribution for the treatment effect—to quantify PoS of a planned study has grown across the industry in recent years, and has now become routine within the authors' company. In this paper, we illustrate some of the benefits of systematically adopting assurance as a quantitative framework to support decision making in drug development through several case‐studies where evaluation of assurance has proved impactful in terms of trial design and in supporting governance‐board reviews of project proposals. In addition, we describe specific features of how the assurance framework has been implemented within our company, highlighting the critical role that prior elicitation plays in this process, and illustrating how the overall assurance calculation may be decomposed into a sequence of conditional PoS estimates which can provide greater insight into how and when different development options are able to discharge risk.